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Amino acids in cardiology, gastroenterology and neurology
Aim. To determine the role of amino acids in cardiology, gastroenterology and neurology.
Materials and methods. The material of the article was the literature data on the use of amino acids in cardiology, 
gastroenterology and neurology, which were processed by methods of generalization and systematization.
Results and discussion. Data on the role of leucine, isoleucine, and valine in the pathogenesis of heart failure 
and the effect on their metabolism for prophylactic and therapeutic purposes are provided. The antiatherogenic role 
of glycine and leucine, taurine and arginine in the metabolic syndrome has been highlighted. The neuroprotective and 
cardioprotective values of L-arginine, and the neurotransmitter value of glutamate have been indicated. The attention 
is focused on the role of amino acids in the implementation of hepatoprotection.
Conclusions. In the pathogenesis of cardiovascular, gastroenterological, neurological diseases a significant role 
is given to amino acids. The analysis of the literature data confirms the rationality of the introduction of drugs containing 
branched-chain amino acids in order to achieve cardioprotective, neuroprotective and hepatoprotective effects.
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Амінокислоти в кардіології, гастроентерології та неврології
Мета дослідження. Визначення ролі амінокислот у кардіології, гастроентерології та неврології.
Матеріали та методи. Матеріалом статті слугували літературні дані щодо застосування амінокислот у кардіо-
логії, гастроентерології та неврології, які були опрацьовані методами узагальнення та систематизації.
Результати та їх обговорення. Надані дані щодо ролі лейцину, ізолейцину, валіну в патогенезі серцевої 
недостатності і впливі на їхній обмін з профілактичною і лікувальною метою. Виділена антиатерогенна роль 
гліцину і лейцину, таурину і аргініну при метаболічному синдромі. Вказано нейропротекторне та кардіопротек-
торне значення L-аргініну, нейротрансміттерне – глутамату. Акцентовано увагу на ролі амінокислот у реалізації 
гепатопротекції.
Висновки. У патогенезі серцево-судинних, гастроентерологічних, неврологічних захворювань важливе місце 
відведене амінокислотам. Проведений аналіз літературних даних підтверджує раціональність введення препа-
ратів, що містять амінокислоти із розгалуженими ланцюгами задля досягнення кардіопротекторної, нейропро-
текторної та гепатопротекторної дії.
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Аминокислоты в кардиологии, гастроэнтерологии и неврологии
Цель исследования. Установление роли аминокислот в кардиологии, гастроэнтерологии и неврологии.
Материалы и методы. Материалом статьи служили литературные данные относительно использования 
аминокислот в кардиологии, гастроэнтерологии и неврологии, которые обрабатывали методами обобщения и 
систематизации.
Результаты и их обсуждение. Предоставлены данные относительно роли лейцина, изолейцина, валина в 
патогенезе сердечной недостаточности и влиянии на их обмен с профилактической и лечебной целью. Выделена 
антиатерогенная роль глицина и лейцина, таурина и аргинина при метаболическом синдроме. Указано нейро-
протекторное и кардиопротекторное значение L-аргинина, нейротрансмиттерное – глутамата. Акцентировано 
внимание на роли аминокислот в реализации гепатопротекции.
Выводы. В патогенезе сердечно-сосудистых, гастроэнтерологических, неврологических заболеваний зна-
чительное место отведено аминокислотам. Проведенный анализ литературных данных подтверждает рацио-
нальность введения препаратов, содержащих аминокислоты с разветвленными цепями для достижения кар-
диопротекторного, нейропротекторного и гепатопротекторного действия.
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Introduction. Amino acids play an extremely im-
portant role in the body, they are substrates for the syn-
thesis of protein molecules, regulate and participate in 
many biochemical processes. A disorder in the metabo-
lism of these compounds, in particular both their defi-
ciency and excess, is very important in the pathogenesis 
of various diseases. Therefore, the correction of anabo-
lism and catabolism of amino acids is one of the thera-
peutic approaches in the treatment of these pathologies.
The aim of the work is to determine the role of ami- 
no acids in cardiology, gastroenterology and neurology.
Materials and methods. The material of the artic- 
le was the literature data on the use of amino acids in 
cardiology, gastroenterology and neurology, which we- 
re processed by methods of generalization and systema- 
tization.
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Results and discussion
Amino acids in cardiology
Heart failure. Branched-chain amino acids (BCAA), 
which include leucine, isoleucine and valine, play an 
important role in the physiology of the normal heart and 
in the pathogenesis of heart failure. Unlike other meta- 
bolites, BCAA are inactivated not only in the liver, but 
also in other tissues: the myocardium, diaphragm, kid-
neys and brain. It suggests that these amino acids are of 
particular importance as bioenergy fuels, especially in 
conditions of chronic hypoxia [1]. In addition, due to 
the stimulation of mitochondrial biogenesis of BCAA 
in the myocardium and skeletal muscles the adaptive 
properties of eukaryotic organisms are improved, and 
the average life expectancy increases [2].
The key enzyme for BCAA catabolism is mitochond- 
rial protein phosphatase (PP2Cm), which provides phos-
phorylation and activation of branched-chain dehydro-
genase complex (BCAA conversion product under the ef- 
fect of aminotransferase). In the normal heart, the acti- 
ve expression of PP2Cm in cardiomyocytes indicates a 
high level of catabolism of these compounds.
However, under severe heart failure, there is a sig-
nificant reduction in the expression of this enzyme, which 
leads to an increase in the number of free BCAAs. At first 
glance, it has a beneficial effect since under hypoxia they 
serve as supplementary nutrients for cardiomyocytes: 
stimulate their hypertrophy and participate in further heart 
remodeling processes.
Moreover, it has been found that PP2Cm deficiency 
and BCAA degradation are not compensatory, but, on 
the contrary, are pathogenetic factors in the development 
of the disease. Continuous activation of mTOR pathway, 
suppression of cardioprotective autophagy of damaged 
cells, a change of the bioenergetic activity of cardio-
myocytes and disturbance of regulation of mitochond- 
rial biochemical processes due to the formation of free 
radicals are all “side effects” of increasing the amount 
of BCAA in the heart [1].
Atherosclerosis. It is well-known that exogenous 
alimentary factors play an important role in the patho-
genesis of atherosclerosis, and consequently, in coro-
nary heart disease (CHD) [3]. But if cholesterol and other 
lipid metabolism products as the etiological factors of 
these diseases have been studied in detail, the role of 
amino acids, their mechanisms of action and the content 
of the diet of patients have not been studied so widely. 
Nowadays, data is available on the involvement of some 
specific amino acids in the process of foamy cell forma-
tion – modified macrophages that absorb lipid deposits 
in the intima of blood vessels and are components of an 
atherosclerotic plaque. 
Analyzing the properties of 20 basic amino acids 
they can be classified as pro- and anti-atherogenic ones 
by the nature of the action on the metabolism. Thus, gly-
cine, cysteine, alanine, leucine, glutamate and glutamin 
have the anti-atherogenic effect. They directly partici-
pate in the foam cells formation, mainly due to modu- 
lation of the cellular metabolism of triglycerides. In the stu- 
dy on cultured macrophages of J774A.1, these amino 
acids significantly (by 24-38 %) decreased the content 
of triglycerides in these cells and weakened the capture 
of very low density lipoprotein (VLDL), carriers of tri-
glycerides by macrophages. In contrast, glutamate and 
glutamine had the pro-atherogenic effect as they con-
tributed to the accumulation of lipids in macrophages 
(by 107 % and 129 %).
Addition of glycine to apolipoprotein E-deficient (apoE-/-) 
mice for 40 days significantly decreased the triglyceride 
levels in the serum and in peritoneal macrophages (MPMs) 
isolated from the mice (by 19 %). In contrast, glutami- 
ne addition significantly increased MPM free radical ge- 
neration and the accumulation of cholesterol and tri-
glycerides (by 48 %), via enhanced uptake of LDL and 
VLDL [4].
A possible mechanism of the anti-atherogenic effect 
of glycine consists in its activating chlorine channels, 
providing glycine-dependent entry of these ions into 
a cell. By regulating the intracellular concentration of 
chlorine the amino acid reduces the accumulation of tri-
glycerides by foamy cells [5].
The studies in human populations, in mice and cultu- 
red macrophages have found that leucine modifies the li-
pid metabolism by enhancing mitochondrial respiration. 
This amino acid is also able to suppress the accumula-
tion of fat by tissues [6].
If the anti-atherogenic effect of leucine is undoubted, 
then with two other BCAAs, valine and isoleucine, this 
is not all that clear. The studies of the peripheral blood 
of patients with atherosclerosis show a connection bet- 
ween this disease and a disorder of the BCAA metabo-
lism. An increase in the level of these two amino acids 
in the blood gives grounds for using laboratory analysis 
results as affirmation of the patients’ diagnosis [7]. This 
is due to the fact that in conditions of constant hypoxia, 
catabolism of BCAA is disturbed; therefore, they accu-
mulate both in the blood and in the cells [8]. Although 
some scientists suggest that elevation of BCAA in the pe-
ripheral blood is explained by the activity of the intesti-
nal microflora rather than food factors [9].
These data confirm the rationality of introducing drugs 
or adding an appropriate amount of leucine, glycine and 
other anti-atherogenic amino acids to the diet of patients 
in order to achieve the cardioprotective effect. At the same 
time, patients should reduce the use of products or me- 
dicines containing pro-atherogenic amino acids gluta-
mate and glutamine. In turn, BCAA can be included in 
the diagnostic markers of atherosclerosis.
Metabolic syndrome. The role of BCAA metabo-
lism products in the development of the metabolic synd- 
rome, in particular insulin resistance, obesity and arte-
rial hypertension, has been experimentally confirmed. 
The metabolic syndrome in mice was induced by feeding 
them with a diet rich in fats and BCAA. As a conse-
quence, constant phosphorylation processes were obser- 
ved in animals in mTOR, JNK and IRS1 (ser307) path-
ways, and the accumulation of acylarnitin in muscles [10].
Recently, it has been suggested that the effects of 
BCAA depend on the metabolic status of the body [11]. 
In addition, the correlation between BCAA and cardio-
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metabolic diseases has been shown to be age-related 
and more common in younger individuals than in the el-
derly [12].
It is believed that taurine, a cysteine derivative, and 
arginine may be components of the standard therapy 
for diabetic patients with cardiovascular complications. 
Experimental results in streptozotocin-induced diabetes 
mice indicate that taurine directly affects the functional 
activity of the myocardium, while in combination with 
arginine, it eliminates the disturbance of the ultrastruc-
ture of cardiomyocytes due to hyperglycemia. This is 
confirmed by echocardiography and electron microscopy, 
and in vivo catheterization [13].
It should be noted that taurine and arginine have pro-
nounced antioxidant properties, regulate the content of 
Ca2+ in the cells of the heart, thus protecting cardiomyo-
cytes against oxidative stress, calcium mechanisms of 
damage and necrosis. [14-16] In addition, taurine indu- 
ces an anti-apoptotic protein Bcl-2 and thus protect the heart 
cells [13].
Therefore, in patients with the metabolic syndrome 
it is expedient to control the level of BCAA and their 
metabolic products, and diabetic patients with cardio-
vascular complications should be included in the treat-
ment plan for arginine and taurine.
Amino acids in neurology
It is well-known that amino acids play an extremely 
important role in the functioning of the central and pe-
ripheral nervous system: tryptophan, tyrosine, histidine 
and arginine are precursors of many neurotransmitters. 
Therefore, both the deficit and the excess of these sub-
stances lead to a variety of neurological disorders [17]. 
We propose to pay attention to the amino acids arginine 
and glutamate, which metabolic disorders play an im-
portant role in the pathogenesis of many pathologies of 
the nervous system.
L-Arginine is an extremely important amino acid 
for the normal brain function. It is not only included in 
the synthesized polypeptide chains in the nerve cells, but 
is a substrate for the formation of urea, creatine, nitric 
oxide, glutamic acid, ornithine, proline and polyamines. 
In turn, these metabolites are involved in many physio- 
logical processes in the central nervous system [18].
Depressive disorders. It is known that L-arginine has 
a neuroprotective property. Nitric oxide (NO), the final 
product of the metabolism of this amino acid, provides 
expression of the hypoxia-inducible factor-1 α, thereby 
preventing neuronal necrosis. [19] In the pathogenesis 
of depressive disorders an important role is played by 
inflammatory changes and expressed oxidative proces- 
ses in the patient’s body. That is why the disorder of 
arginine catabolism, and consequently, the reduction of 
NO production, leads to increased oxidative stress and 
necrotic changes in the brain of patients, thus exacer-
bating depression [20].
The MELAS-syndrome (mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes). 
After a 9-year clinical study of sick children and adults 
with this syndrome scientists concluded that oral and 
intravenous administration of L-arginine yields good 
results in relieving the symptoms of this pathology. Oral 
administration of the amino acid prevents the develop-
ment of stroke and reduces the degree of their severity. 
Intravenous administration of L-arginine helped to eli- 
minate the main four symptoms of the disease: heada- 
ches, nausea/vomiting, loss of consciousness and visual 
impairment [21].
Alzheimer’s disease (AD). Some scientists believe 
that L-arginine may be a potential marker for AD in older 
adults since in clinical trials in patients with this diag-
nosis the plasma level of this amino acid is significantly 
elevated. This indicates a significant imbalance of the me-
tabolism of arginine in the central nervous system. [22] 
In contrast to patients with AD, individuals with good 
memory have lower levels of L-arginine [23].
In patients with AD the disturbance of expression of 
arginase [24] and NO-synthase [25], enzymes that pro-
vide catabolism of arginine and contribute to its transfor-
mation into nitric oxide (NO), is also observed in the brain. 
In the experimental modeling of AD in mice the intro-
duction of arginase significantly reduced the symptoms 
of the disease [26].
Thus, in the case of depressive disorders and the 
MELAS- syndrome, there is a deficiency of L-arginine, 
which elimination is the aim of the pathogenetic thera-
py. On the contrary, in the case of Alzheimer’s disease 
the disorder of the catabolism of this amino acid and 
the accumulation of it over the normal level cause the 
characteristic symptoms. Therefore, the substitution en-
zyme therapy is indicated for this disease.
Glutamate is a powerful excitatory neurotransmit-
ter secreted by nerve cells in the brain. It transmits sig-
nals between neurons and under normal conditions plays 
an important role in the learning and memory processes, 
the storage of information in the brain.
Multiple sclerosis. A neurotransmitter glutamate is 
involved in autoimmune demyelination in multiple sclero-
sis (MS). This is confirmed by statistical studies of the le- 
vel of this amino acid in the cerebrospinal fluid [27], 
plasma [28], lacrimal gland secretion [29]: the level of 
this amino acid was much higher in patients with MS 
compared to control groups of healthy adult patients. 
The pathogenesis of lesions in MS is due to neurotoxic 
effects of glutamate on oligodendrocytes and neurons 
in the central nervous system. The experimental studies 
have shown that the excitatory glutaminergic effects me-
diated by N-methyl-D-aspartate (NMDA) and α-amino- 
3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) re- 
ceptors also cause damage to axons, which causes charac-
teristic symptoms of the disease [27].
Frontotemporal dementia. Currently, the clinical 
studies prove that glutamate is a key neurotransmitter 
in the pathogenesis of front-temporal dementia (FTD). 
Experimental animals with FTD showed selective hypofunc-
tion of NMDA and AMPA receptors in glutaminergic py-
ramidal neurons normally accumulated in the frontal and 
temporal cortex. Other in vivo experiments using nonin-
vasive transcranial magnetic stimulation indicate the in-
volvement of the glutaminergic system in the development 
of both sporadic and hereditary forms of FTD [30].
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Thus, if MS is characterized by a significant incre- 
ase in the amount of glutamate in the brain, in FTD, 
on the contrary, there is a deficiency of it. Regulation 
of the metabolism of glutamate and the use of receptor 
blockers to it should be one of the directions of MS therapy, 
whereas in FTD, the treatment approach should be aimed 
at eliminating the deficit of the neurotransmitter, like do-
paminergic therapy in Parkinson’s disease and choliner-
gic one in Alzheimer’s disease.
Amino acids in gastroenterology
Disturbances of metabolism of branched-chain ami-
no acids occur also in the pathogenesis of diseases of 
the gastrointestinal tract, in particular liver pathologies.
BCAA is not only a substrate for the synthesis of pro-
teins – they are also involved in the regulation of the me-
tabolism of different nutrients. Patients with chronic li- 
ver diseases (chronic and alcoholic hepatitis, prima-
ry biliary and cryptogenic cirrhosis) are characterized 
by a deficiency of BCAA and, therefore, have a variety 
of metabolic disorders. A significant decrease in the con-
centration of BCAA is considered a diagnostic marker 
of cirrhosis and a criterion for the severity of liver da- 
mage.
Liver encephalopathy (LE) is a severe consequence 
of cirrhosis and is due to the toxic effects of bile acids on 
neurons and, consequently, the development of the he-
patic coma. It is important that a mild form of LE is ty- 
pical for almost 80 % of patients with chronic liver di- 
sease, and it significantly affects their level of life. A major 
factor in the development of BCAA deficiency is hyper-
ammonemia. In addition to the urea cycle in the liver, 
ammonium is also detoxified in the skeletal muscle with 
the participation of BCAA. Thus, the prescription of these 
amino acids is a potential therapeutic strategy to elimi-
nate the symptoms of LE [31]. These data have been 
confirmed by 11 randomized clinical trials [32].
Taking into account that cirrhosis is a precancerous 
condition it should be noted that the amino acid imba- 
lance is a significant risk factor for the development of 
hepatocellular carcinoma (HCC) in patients with cirrhotic 
changes in the liver. The studies have shown that BCAA 
administration reduces HCC risk and prolongs life ex-
pectancy in these patients [33]. This is due to the fact 
that BCAA not only promotes detoxification and elimi-
nation of hyperammonemia, but also prevents prolife- 
ration of tumor cells by inducing apoptosis [34]. They 
also stimulate the selection of growth factors, enhance 
regeneration of hepatocytes, and increase the number of 
parenchymal cells.
In addition, BCAA increases immunity in patients with 
cirrhosis: improves the phagocytic function of neutro-
phils and affects the proliferation of lymphocytes, pre-
venting irreversible damage to dendritic cells that re-
lease interleukin-12, a powerful natural killer activator. 
The immuno-stimulating effect of these amino acids is 
particularly important since bacterial (often opportunistic) 
infections are considered one of the most common cau- 
ses of death in patients with cirrhosis.
Thus, the presciption of BCAA (as granules or as 
food products) is pathogenetically feasible as it prevents 
the development of liver failure and infectious diseases 
in patients with cirrhosis [33].
Conversely, in patients with nonalcoholic fatty liver 
disease (NAFLD) and obesity an increase in the con-
centration of BCAA (including isoleucine and valine) 
in the plasma is observed. Scientists consider the excess 
of BCAA as a result of high insulin resistance in these 
patients and an enhanced disintegration of proteins [35].
Consequently, in the pathogenesis of liver disease, 
both deficiency and excess BCAA are possible. Taking 
this into account the amino acid exchange in these pa-
tients can be corrected.
Conclusions and prospects of further research
In the pathogenesis of cardiovascular, gastroentero-
logical, neurological diseases a significant role is given 
to amino acids. The analysis of the literature data con-
firms the rationality of the introduction of drugs con-
taining branched-chain amino acids in order to achieve 
cardioprotective, neuroprotective and hepatoprotective 
effects.
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